3D1015 Injection for Patients With mCRPC

This open-label clinical study investigates 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive intravenous infusions of 3D1015, with treatment regimens dynamically individualized to optimize patient safety and outcomes. The primary objectives are to assess the safety, tolerability, and dosimetry of the injection. Secondary objectives include evaluating preliminary anti-tumor efficacy and exploring the optimal dosing regimen.

Trial Details

NCT ID

NCT07537010

Phase

PHASE1

Sponsor

Chunjing Yu

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Lu 177-PSMA-3D1015 Injection

Locations (sample)

Wuxi, Jiangsu, China|31.56887,120.28857

Key Eligibility Criteria

Capable of understanding and providing written informed consent. Willing and able to comply with all study requirements, treatments, and scheduled …
Male, aged 18 years or older.
Histologically or cytologically confirmed prostate adenocarcinoma.
Castrate levels of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →